sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trojlôžkových kombinovaná liečba) ako doplnok stravy a cvičenia pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).
sitagliptin/metformin hcs 50 mg/1 000 mg filmom obalené tablety
hcs bvba, belgicko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin/metformin hcs 50 mg/850 mg filmom obalené tablety
hcs bvba, belgicko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin vitabalans 500 mg filmom obalené tablety
vitabalans oy, fínsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin vitabalans 1000 mg filmom obalené tablety
vitabalans oy, fínsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin mylan xr 750 mg
mylan ireland limited, Írsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin mylan xr 500 mg
mylan ireland limited, Írsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin teva xr 1000 mg
teva b.v., holandsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin teva xr 750 mg
teva b.v., holandsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)